Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies

Inclusion Criteria: * Age 18 to 75 years (inclusive) at screening. * Able to lie still on the scanning bed for 0.5 hours. * Willing to sign informed consent and able to comply with protocol requirements. * Histologically/cytologically confirmed diagnosis of multiple myeloma (MM), non-Hodgkin lymphoma (NHL), or acute myeloid leukaemia (AML) according to the 2022 WHO Classification of Haematolymphoid Tumours. Exclusion Criteria: * Has claustrophobia or any other condition that prevents tolerance of imaging procedures * Has undergone major surgery within 3 months prior to screening, or plans to undergo surgery during the study period. * Has received any other radiopharmaceutical imaging agent or therapeutic radiopharmaceutical within 30 days prior to screening. * Is pregnant or lactating at screening. * Is a woman of childbearing potential or a man who does not agree to use effective contraception during the study (from signing informed consent) and for 3 months after study drug administration. * Has a known allergy to alcohol or any component of the investigational product, or has other allergies judged by the investigator to increase the participant's risk. * Has clinically significant cardiovascular disease within 6 months prior to screening (e.g., myocardial infarction, unstable angina, symptomatic congestive heart failure, uncontrolled severe arrhythmia). * Has uncontrolled hypertension, or a history of coagulopathy or coagulation disorders. * Has been diagnosed with another malignancy (other than the target haematological disease) within 5 years prior to 68Ga-EV203 administration. * Has received any systemic anti-cancer therapy within 2 weeks prior to planned 68Ga-EV203 administration, or radiotherapy within 8 weeks prior to planned administration. * Has any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.